Jade Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Cash & Equivalents	88.44	69.39
Short-Term Investments	247.72	-
Cash & Short-Term Investments	336.16	69.39
Cash Growth	384.47%	-
Prepaid Expenses	12.66	0.27
Total Current Assets	348.82	69.65
Property, Plant & Equipment	0.9	-
Other Long-Term Assets	0.07	3.15
Total Assets	349.78	72.8
Accounts Payable	2.02	1.29
Accrued Expenses	14.39	9.63
Current Portion of Leases	0.13	-
Other Current Liabilities	-	1.08
Total Current Liabilities	16.54	12
Long-Term Debt	-	107.6
Long-Term Leases	0.72	-
Total Liabilities	17.26	119.6
Common Stock	0.01	0
Additional Paid-In Capital	506.77	0.18
Retained Earnings	-174.39	-46.98
Comprehensive Income & Other	0.13	-
Total Common Equity	332.52	-46.8
Shareholders' Equity	332.52	-46.8
Total Liabilities & Equity	349.78	72.8
Total Debt	0.85	107.6
Net Cash (Debt)	335.31	-38.21
Net Cash Per Share	10.69	-12.11
Filing Date Shares Outstanding	49.32	5.82
Total Common Shares Outstanding	49.32	5.82
Working Capital	332.28	57.66
Book Value Per Share	6.74	-8.04
Tangible Book Value	332.52	-46.8
Tangible Book Value Per Share	6.74	-8.04

Source: S&P Capital IQ. Standard template. Financial Sources.